ScholarIQanswers from OpenAlex
Maharaja Sayajirao University of Baroda
InstitutionResearch output, impact & collaborations
Maharaja Sayajirao University of Baroda is a institution indexed in ScholarIQ from OpenAlex.
What is known about Maharaja Sayajirao University of Baroda?
ScholarIQrecord summary
Maharaja Sayajirao University of Baroda is a research organisation in Vadodara, IN. OpenAlex records 13,044 works and 432,684 citations for it. 3,571 researchers list it as their most recent affiliation.
How many works does Maharaja Sayajirao University of Baroda have?
ScholarIQindexed works
Maharaja Sayajirao University of Baroda has 13,044 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Maharaja Sayajirao University of Baroda have?
ScholarIQcitation count
Maharaja Sayajirao University of Baroda has 432,684 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Maharaja Sayajirao University of Baroda?
ScholarIQresearcher count
Maharaja Sayajirao University of Baroda has 3,571 researchers in the ScholarIQ index.
What is the average h-index at Maharaja Sayajirao University of Baroda?
ScholarIQavg h-index
Maharaja Sayajirao University of Baroda has an average h-index of 56.3 in OpenAlex.
What is the ROR of Maharaja Sayajirao University of Baroda?
ScholarIQror
The ROR for Maharaja Sayajirao University of Baroda is on the source record.
What is the OpenAlex record for Maharaja Sayajirao University of Baroda?
ScholarIQopenalex
The OpenAlex for Maharaja Sayajirao University of Baroda is on the source record.
What is the Wikidata of Maharaja Sayajirao University of Baroda?
ScholarIQwikidata
The Wikidata for Maharaja Sayajirao University of Baroda is on the source record.
Who are the most-cited researchers behind Maharaja Sayajirao University of Baroda?
ScholarIQtop researchers by citations
What are the most-cited papers on Maharaja Sayajirao University of Baroda?
ScholarIQmost cited works
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink, Sangeetha M. Reddy, Jianjun Gao, Shaojun Zhang, Rafet Başar, Rohit Thakur, Keren Yizhak, Moshe Sade-Feldman, Jorge Blando, Guangchun Han, Vancheswaran Gopalakrishnan, Yuanxin Xi, Hao Zhao, Rodabe Navroze Amaria, Hussein Tawbi, Alexandria P. Cogdill, Wenbin Liu, Valerie S. LeBleu, Fernanda G. Kugeratski, Sapna P. Patel, Michael A. Davies, Patrick Hwu, Jeffrey E. Lee, Jeffrey E. Gershenwald, Anthony Lucci, Reetakshi Arora, Scott E. Woodman, Emily Z. Keung, Pierre-Olivier Gaudreau, Alexandre Reuben, Christine N. Spencer, Elizabeth M. Burton, Lauren E. Haydu, Alexander J. Lazar, Roberta Zapassodi, Courtney W. Hudgens, Deborah A. Ledesma, SuFey Ong, Michael Bailey, Sarah Warren, Disha Rao, Oscar Krijgsman, Elisa A. Rozeman, Daniel S. Peeper, Christian U. Blank, Ton N. Schumacher, Lisa H. Butterfield, Monika A. Zelazowska, Kevin M. McBride, Raghu Kalluri, James P. Allison, Florent Petitprez, Wolf H. Fridman, Catherine Sautès‐Fridman, Nir Hacohen, Katayoun Rezvani, Padmanee Sharma, Michael T. Tetzlaff, Linghua Wang, Jennifer A. Wargo
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom, Siwen Hu‐Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach‐Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari Kendra, Richard C. Wu, Craig Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James Warneke, Alexandra P. Ikeguchi, Jose Eugenio Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy C. Hsueh, Kim Margolin, Warren Chow, Kenneth F. Grossmann, Eliana Dietrich, Víctor G. Prieto, Michael Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa A. Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N. Amaria, Sangeetha M. Reddy, Hussein A. Tawbi, Michael A. Davies, Merrick I. Ross, Isabella C. Glitza, Janice N. Cormier, Carol M. Lewis, Wen-Jen Hwu, Ehab Hanna, Adi Diab, Michael K. Wong, Richard E. Royal, Neil D. Gross, Randal S. Weber, Stephen Y. Lai, Richard A. Ehlers, Jorge Blando, Denái R. Milton, Scott E. Woodman, Robin Kageyama, Daniel K. Wells, Patrick Hwu, Sapna P. Patel, Anthony Lucci, Amy C. Hessel, Jeffrey E. Lee, Jeffrey E. Gershenwald, Lauren Simpson, Elizabeth M. Burton, Liberty Posada, Lauren E. Haydu, Linghua Wang, Shaojun Zhang, Alexander J. Lazar, Courtney W. Hudgens, Vancheswaran Gopalakrishnan, Alexandre Reuben, Miles C. Andrews, Christine N. Spencer, Víctor G. Prieto, Padmanee Sharma, James P. Allison, Michael T. Tetzlaff, Jennifer A. Wargo
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, Alfie Abbott, Ashraf Omar Abdelaziz, Sherif Abdelbadiee, Mohamed A. O. Abdelfattah, Basir Abdul, Althaf Abdul Rasheed, Rezan A. Kadir, Abdulfatahi Abdulmumeen, Niyaz Abdulshukkoor, Kula Abdusamad, Yazeed Abed El Khaleq, Mai Abedalla, Abeer UA Abeer Ul Amna, Adebanke Aboaba, Hani Abo-Leyah, Ahmed Abou-Haggar, Mahmoud Abouibrahim, Miriam Abraham, Tizzy Abraham, Abraheem Abraheem, Judith Abrams, Hyacinth-John Abu, Ahmad Abu-Arafeh, Syed M Abubacker, Akata Abung, Yaa Aceampong, Devikumar Acharya, Janet Acheson, Andrés Acosta, Catherine Acton, Jacqueline Adabie-Ankrah, Fiona Adam, Matthew Adam, Huzaifa Adamali, Carol Adams, Kate Adams, Richard Adams, Tim Adams, Malgorzata Adamus, Kirsty Adcock, Aderonke Adebiyi, Ken Adegoke, Vicki Adell, Aldrin Adeni, Sherna Adenwalla, Oluwasegun A Adesemoye, Emmanuel O Adewunmi, Joyce Adeyemi, Elizabeth Adeyeye, Gabrielle Adkins, Adnan Adnan, John Aeron‐Thomas, Lynn Afari, Debbie Affleck, Carmel Afnan, Deborah Afolabi, Muhammad Abdur Rahman Afridi, Rachel Agbeko, Chris Agbo, Sunil Aggarwal, Arameh Aghababaie, Judith Agwada-Akeru, Kwame A Agyapong, Shafana Ahamed Sadiq, Mohamed H Ahammed Nazeer, Jonathan Ah-Chuen, Mahin Ahmad, Ashar Ahmed, Bilal Ahmed, Forizuddin Ahmed, Iram Ahmed, Irshad Ahmed, Liban Ahmed, Maria C Ahmed, Muhammad S. Ahmed, Naseer Ahmed, Nausheen Ahmed, Osama Ahmed, Rajia A Ahmed, Rizwan Ahmed, Saif Ahmed, Sammiya Ahmed, Sara Ahmed, Syed Haris Ahmed, Roa Ahmed Ali, Sana Ahmer, Dhiraj Ail, Adam Ainsley, Mark Ainsworth, Myriam Aissa, Lucy Aitchson, Lindianne Aitken, Bini Ajay, Abdulakeem Ajibode, Ayesha Ajmi, Muhammad Nadeem Akhtar, Nasim Akhtar
Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
Laszlo Radvanyi, Chantale Bernatchez, Minying Zhang, Patricia S. Fox, Priscilla Miller, Jessica Chacon, Richard Wu, Gregory Lizée, Sandy Mahoney, Gladys Alvarado, Michelle R. Glass, Valen E. Johnson, John D. McMannis, Elizabeth J. Shpall, Víctor G. Prieto, Nicholas Papadopoulos, Kevin Kim, Jade Homsi, Agop Y. Bedikian, Wen‐Jen Hwu, Sapna P. Patel, Merrick I. Ross, Jeffrey E. Lee, Jeffrey E. Gershenwald, Anthony Lucci, Richard E. Royal, Janice N. Cormier, Michael A. Davies, Rahmatu Mansaray, Orenthial J. Fulbright, Christopher Toth, Renjith Ramachandran, Seth Wardell, Audrey M. Gonzalez, Patrick Hwu
How much of the research on Maharaja Sayajirao University of Baroda is open access?
ScholarIQopen access share
83%OPEN ACCESS